Skip to main content
Top
Published in: Medical Oncology 6/2018

Open Access 01-06-2018 | Original Paper

Reduced intensity conditioning increases risk of severe cGVHD: identification of risk factors for cGVHD in a multicenter setting

Authors: Gabriel Afram, Jose Antonio Pérez Simón, Mats Remberger, Teresa Caballero-Velázquez, Rodrigo Martino, Jose Luis Piñana, Olle Ringden, Albert Esquirol, Lucia Lopez-Corral, Irene Garcia, Oriana López-Godino, Jordi Sierra, Dolores Caballero, Per Ljungman, Lourdes Vazquez, Hans Hägglund

Published in: Medical Oncology | Issue 6/2018

Login to get access

Abstract

Chronic graft-versus-host disease (cGVHD) remains a major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT). Aim is to identify risk factors for the development of cGVHD in a multicenter setting. Patients transplanted between 2000 and 2006 were analyzed (n = 820). Donors were HLA-identical siblings (57%), matched unrelated donors (30%), and HLA-A, B or DR antigen mismatched (13%). Reduced intensity conditioning (RIC) was given to 65% of patients. Overall incidence of cGVHD was 46% for patients surviving more than 100 days after HSCT (n = 747). Older patient age [HR 1.15, p < 0.001], prior acute GVHD [1.30, p = 0.024], and RIC [1.36, p = 0.028] increased overall cGVHD. In addition, RIC [4.85, p < 0.001], prior aGVHD [2.14, p = 0.001] and female donor to male recipient [1.80, p = 0.008] increased the risk of severe cGVHD. ATG had a protective effect for both overall [0.41, p < 0.001] and severe cGVHD [0.20, p < 0.001]. Relapse-free survival (RFS) was impaired in patients with severe cGVHD. RIC, prior aGVHD, and female-to-male donation increase the risk of severe cGVHD. ATG reduces the risk of all grades of cGVHD without hampering RFS. GVHD prophylaxis may be tailored according to the risk profile of patients.
Literature
2.
go back to reference Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, et al. Chronic-graft-versus-host syndrome in man: a long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69:204–17.CrossRefPubMed Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, et al. Chronic-graft-versus-host syndrome in man: a long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69:204–17.CrossRefPubMed
3.
go back to reference Thomas E, Storb R, Clift RA, Fefer A, Johnson FL, Neiman PE, et al. Bone marrow transplantation (first of two parts). N Engl J Med. 1975;17(292):832–43.CrossRef Thomas E, Storb R, Clift RA, Fefer A, Johnson FL, Neiman PE, et al. Bone marrow transplantation (first of two parts). N Engl J Med. 1975;17(292):832–43.CrossRef
4.
go back to reference Thomas E, Storb R, Clift RA, Fefer A, Johnson FL, Neiman PE, et al. Bone-marrow transplantation (second of two parts). N Engl J Med. 1975;24(292):895–902.CrossRef Thomas E, Storb R, Clift RA, Fefer A, Johnson FL, Neiman PE, et al. Bone-marrow transplantation (second of two parts). N Engl J Med. 1975;24(292):895–902.CrossRef
6.
go back to reference Carlens S, Ringden O, Remberger M, Lönnqvist B, Hägglund H, Klaesson S, et al. Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis. Bone Marrow Transpl. 1998;22:755–61.CrossRef Carlens S, Ringden O, Remberger M, Lönnqvist B, Hägglund H, Klaesson S, et al. Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis. Bone Marrow Transpl. 1998;22:755–61.CrossRef
7.
go back to reference Ratanatharathorn V, Ayash L, Lazarus HM, Fu J, Uberti JP. Chronic graft-versus-host disease: clinical manifestation and therapy. Bone Marrow Transpl. 2001;28:121–9.CrossRef Ratanatharathorn V, Ayash L, Lazarus HM, Fu J, Uberti JP. Chronic graft-versus-host disease: clinical manifestation and therapy. Bone Marrow Transpl. 2001;28:121–9.CrossRef
8.
go back to reference Atkinson K, Horowitz MM, Gale RP, van Bekkum DW, Gluckman E, Good RA, et al. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood. 1990;75(12):2459–64.PubMed Atkinson K, Horowitz MM, Gale RP, van Bekkum DW, Gluckman E, Good RA, et al. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood. 1990;75(12):2459–64.PubMed
9.
go back to reference Eapen M, Logan B, Confer D, Haagenson M, Wagner J, Weisdorf DJ, et al. Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival. Biol Blood Marrow Transpl. 2007;13:1461–8.CrossRef Eapen M, Logan B, Confer D, Haagenson M, Wagner J, Weisdorf DJ, et al. Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival. Biol Blood Marrow Transpl. 2007;13:1461–8.CrossRef
10.
go back to reference Perez-Simon JA, Afram G, Martino R, Pinana JL, Caballero-Velazquez T, Ringden O, et al. Evaluation of prognostic factors among patients with chronic graft-versus-host disease. Haematologica. 2012;97(8):1187–95.CrossRefPubMedPubMedCentral Perez-Simon JA, Afram G, Martino R, Pinana JL, Caballero-Velazquez T, Ringden O, et al. Evaluation of prognostic factors among patients with chronic graft-versus-host disease. Haematologica. 2012;97(8):1187–95.CrossRefPubMedPubMedCentral
11.
go back to reference Bacigalupo A, Lamparelli T, Barisione G, Bruzzi P, Guidi S, Alessandrino PE, et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transpl. 2006;12(5):560–5.CrossRef Bacigalupo A, Lamparelli T, Barisione G, Bruzzi P, Guidi S, Alessandrino PE, et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transpl. 2006;12(5):560–5.CrossRef
12.
go back to reference Filipovich A, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Am Soc Blood Marrow Transpl. 2005;11:945–55.CrossRef Filipovich A, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Am Soc Blood Marrow Transpl. 2005;11:945–55.CrossRef
13.
go back to reference Remberger M, Ringden O, Hägglund H, Svahn BM, Ljungman P, Uhlin M, et al. A high antithymocyte globulin dose increases the risk of relapse after reduced intensity conditioning HSCT with unrelated donors. Clin Transpl. 2013;27(4):E368–74. https://doi.org/10.1111/ctr.12131 (Epub 2013 May 22, 2013).CrossRef Remberger M, Ringden O, Hägglund H, Svahn BM, Ljungman P, Uhlin M, et al. A high antithymocyte globulin dose increases the risk of relapse after reduced intensity conditioning HSCT with unrelated donors. Clin Transpl. 2013;27(4):E368–74. https://​doi.​org/​10.​1111/​ctr.​12131 (Epub 2013 May 22, 2013).CrossRef
14.
go back to reference Fine J, Gray R. Proportional hazard model for the sub-distribution of competing risks. J Am Stat Assoc. 1999;94:496–509.CrossRef Fine J, Gray R. Proportional hazard model for the sub-distribution of competing risks. J Am Stat Assoc. 1999;94:496–509.CrossRef
15.
go back to reference Kolb HJ, Schmid C, Barrett AJ, Schendel DJ. Graft-versus-leukemia reactions in allogeneic chimeras. Blood. 2004;103(3):767–76 (Epub 2003 Sep 4, 2004).CrossRefPubMed Kolb HJ, Schmid C, Barrett AJ, Schendel DJ. Graft-versus-leukemia reactions in allogeneic chimeras. Blood. 2004;103(3):767–76 (Epub 2003 Sep 4, 2004).CrossRefPubMed
17.
go back to reference Lee SJ, Klein JP, Barrett AJ, Ringden O, Antin JH, Cahn JY, et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood. 2002;100(2):406–14.CrossRefPubMed Lee SJ, Klein JP, Barrett AJ, Ringden O, Antin JH, Cahn JY, et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood. 2002;100(2):406–14.CrossRefPubMed
18.
go back to reference Saillard C, Crocchiolo R, Furst S, El-Cheikh J, Castagna L, Signori A, et al. National Institutes of Health classification for chronic graft-versus-host disease predicts outcome of allo-hematopoietic stem cell transplant after fludarabine-busulfan-antithymocyte globulin conditioning regimen. Leuk Lymphoma. 2014;55(5):1106–12.CrossRefPubMed Saillard C, Crocchiolo R, Furst S, El-Cheikh J, Castagna L, Signori A, et al. National Institutes of Health classification for chronic graft-versus-host disease predicts outcome of allo-hematopoietic stem cell transplant after fludarabine-busulfan-antithymocyte globulin conditioning regimen. Leuk Lymphoma. 2014;55(5):1106–12.CrossRefPubMed
19.
go back to reference Couriel DR, Saliba RM, Giralt S, Khouri I, Andersson B, de Lima M, et al. Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. BBMT. 2004;10:178–85. Couriel DR, Saliba RM, Giralt S, Khouri I, Andersson B, de Lima M, et al. Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. BBMT. 2004;10:178–85.
20.
go back to reference Cremer B, Sandmaier BM, Bethge W, Lange T, Goede V, Holtick U, et al. Reduced intensity conditioning in allogeneic stem cell transplantation for hematological malignancies: a historical perspective. Onkologie. 2011;34:710–5.CrossRefPubMed Cremer B, Sandmaier BM, Bethge W, Lange T, Goede V, Holtick U, et al. Reduced intensity conditioning in allogeneic stem cell transplantation for hematological malignancies: a historical perspective. Onkologie. 2011;34:710–5.CrossRefPubMed
21.
go back to reference Flowers ME, Inamoto Y, Carpenter PA, Lee SJ, Kiem HP, Petersdorf EW, et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood. 2011;117(11):3214–9.CrossRefPubMedPubMedCentral Flowers ME, Inamoto Y, Carpenter PA, Lee SJ, Kiem HP, Petersdorf EW, et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood. 2011;117(11):3214–9.CrossRefPubMedPubMedCentral
23.
go back to reference Mohty M, Bay JO, Faucher C, Choufi B, Bilger K, Tournilhac O, et al. Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. Blood. 2003;102(2):470–6 (Epub 2003 Mar 20, 2003).CrossRefPubMed Mohty M, Bay JO, Faucher C, Choufi B, Bilger K, Tournilhac O, et al. Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. Blood. 2003;102(2):470–6 (Epub 2003 Mar 20, 2003).CrossRefPubMed
24.
go back to reference Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR, et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 2009;10(9):855–64. https://doi.org/10.1016/s1470-2045(09)70225-6 (Epub 2009 Aug 18, 2009).CrossRefPubMed Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR, et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 2009;10(9):855–64. https://​doi.​org/​10.​1016/​s1470-2045(09)70225-6 (Epub 2009 Aug 18, 2009).CrossRefPubMed
26.
go back to reference Langston AA, Prichard JM, Muppidi S, Nooka A, Lechowicz MJ, Lonial S, et al. Favorable impact of pre-transplant ATG on outcomes of reduced-intensity hematopoietic cell transplants from partially mismatched unrelated donors. Bone Marrow Transpl. 2014;49(2):185–9. https://doi.org/10.1038/bmt.2013.168 (Epub 2013 Oct 28, 2014).CrossRef Langston AA, Prichard JM, Muppidi S, Nooka A, Lechowicz MJ, Lonial S, et al. Favorable impact of pre-transplant ATG on outcomes of reduced-intensity hematopoietic cell transplants from partially mismatched unrelated donors. Bone Marrow Transpl. 2014;49(2):185–9. https://​doi.​org/​10.​1038/​bmt.​2013.​168 (Epub 2013 Oct 28, 2014).CrossRef
27.
go back to reference Slack JL, Dueck AC, Fauble VD, Sproat LO, Reeder CB, Noel P, et al. Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch. Biol Blood Marrow Transpl. 2013;19(8):1167–74. https://doi.org/10.1016/j.bbmt.2013.05.001 (Epub 2013 May 7, 2013).CrossRef Slack JL, Dueck AC, Fauble VD, Sproat LO, Reeder CB, Noel P, et al. Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch. Biol Blood Marrow Transpl. 2013;19(8):1167–74. https://​doi.​org/​10.​1016/​j.​bbmt.​2013.​05.​001 (Epub 2013 May 7, 2013).CrossRef
28.
go back to reference Russell JA, Turner AR, Larratt L, Chaudhry A, Morris D, Brown C, et al. Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched pair analysis. Biol Blood Marrow Transpl. 2007;13(3):299–306.CrossRef Russell JA, Turner AR, Larratt L, Chaudhry A, Morris D, Brown C, et al. Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched pair analysis. Biol Blood Marrow Transpl. 2007;13(3):299–306.CrossRef
29.
go back to reference Bacigalupo A, Lamparelli T, Bruzzi B, Guidi S, Alessandrino PE, Bartolomeo P, et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood. 2001;98(10):2942–7.CrossRefPubMed Bacigalupo A, Lamparelli T, Bruzzi B, Guidi S, Alessandrino PE, Bartolomeo P, et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood. 2001;98(10):2942–7.CrossRefPubMed
31.
go back to reference Devillier R, Crocchiolo R, Castagna L, Furst S, El Cheikh J, Faucher C, et al. The increase from 2.5 to 5 mg/kg of rabbit anti-thymocyte-globulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients with myeloid malignancies undergoing allo-SCT. Bone Marrow Transpl. 2012;47(5):639–45. https://doi.org/10.1038/bmt.2012.3 (Epub 2012 Feb 6, 2012).CrossRef Devillier R, Crocchiolo R, Castagna L, Furst S, El Cheikh J, Faucher C, et al. The increase from 2.5 to 5 mg/kg of rabbit anti-thymocyte-globulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients with myeloid malignancies undergoing allo-SCT. Bone Marrow Transpl. 2012;47(5):639–45. https://​doi.​org/​10.​1038/​bmt.​2012.​3 (Epub 2012 Feb 6, 2012).CrossRef
Metadata
Title
Reduced intensity conditioning increases risk of severe cGVHD: identification of risk factors for cGVHD in a multicenter setting
Authors
Gabriel Afram
Jose Antonio Pérez Simón
Mats Remberger
Teresa Caballero-Velázquez
Rodrigo Martino
Jose Luis Piñana
Olle Ringden
Albert Esquirol
Lucia Lopez-Corral
Irene Garcia
Oriana López-Godino
Jordi Sierra
Dolores Caballero
Per Ljungman
Lourdes Vazquez
Hans Hägglund
Publication date
01-06-2018
Publisher
Springer US
Published in
Medical Oncology / Issue 6/2018
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-018-1127-2

Other articles of this Issue 6/2018

Medical Oncology 6/2018 Go to the issue